Bridgebio Pharma Stock Price on August 6, 2024
| BBIO Stock | USD 27.49 1.05 3.97% |
Below is the normalized historical share price chart for BridgeBio Pharma extending back to June 27, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of BridgeBio Pharma stands at 27.49, as last reported on the 28th of November, with the highest price reaching 28.20 and the lowest price hitting 26.25 during the day.
If you're considering investing in BridgeBio Stock, it is important to understand the factors that can impact its price. As of now, BridgeBio Stock is very steady. BridgeBio Pharma secures Sharpe Ratio (or Efficiency) of 0.012, which signifies that the company had a 0.012% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for BridgeBio Pharma, which you can use to evaluate the volatility of the firm. Please confirm BridgeBio Pharma's Mean Deviation of 2.75, risk adjusted performance of 0.0506, and Downside Deviation of 2.88 to double-check if the risk estimate we provide is consistent with the expected return of 0.0441%.
At this time, BridgeBio Pharma's Liabilities And Stockholders Equity is very stable compared to the past year. As of the 28th of November 2024, Issuance Of Capital Stock is likely to grow to about 472.3 M, though Total Stockholder Equity is likely to grow to (1.3 B). . At this time, BridgeBio Pharma's Price To Sales Ratio is very stable compared to the past year. As of the 28th of November 2024, Price Sales Ratio is likely to grow to 741.75, while Price Earnings Ratio is likely to drop (10.73). BridgeBio Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 27th of June 2019 | 200 Day MA 27.1762 | 50 Day MA 24.97 | Beta 1.086 |
BridgeBio |
Sharpe Ratio = 0.012
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BBIO |
Estimated Market Risk
| 3.69 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BridgeBio Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BridgeBio Pharma by adding BridgeBio Pharma to a well-diversified portfolio.
Price Book 123.6828 | Enterprise Value Ebitda (9.40) | Price Sales 23.8575 | Shares Float 128.2 M | Wall Street Target Price 48.525 |
BridgeBio Pharma Main Headline on 6th of August 2024
Acquisition by Thomas Trimarchi of 3160 shares of BridgeBio ... by Thomas Trimarchi
Filed transaction by BridgeBio Pharma Officer: President And Coo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
BridgeBio Pharma Valuation on August 6, 2024
It is possible to determine the worth of BridgeBio Pharma on a given historical date. On August 6, 2024 BridgeBio was worth 25.73 at the beginning of the trading date compared to the closed value of 24.87. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of BridgeBio Pharma stock. Still, in general, we apply an absolute valuation method to find BridgeBio Pharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of BridgeBio Pharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against BridgeBio Pharma's related companies.
| Open | High | Low | Close | Volume | |
| 24.15 | 25.75 | 24.12 | 25.50 | 1,782,345 | |
08/06/2024 | 25.73 | 25.73 | 24.75 | 24.87 | 1,695,080 |
| 25.45 | 25.45 | 23.92 | 23.92 | 1,523,554 |
| Backtest BridgeBio Pharma | | | BridgeBio Pharma History | | | BridgeBio Pharma Valuation | Previous | Next |
BridgeBio Pharma Trading Date Momentum on August 6, 2024
| On August 07 2024 BridgeBio Pharma was traded for 23.92 at the closing time. The top price for the day was 25.45 and the lowest listed price was 23.92 . The trading volume for the day was 1.5 M. The trading history from August 7, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 3.82% . The overall trading delta against the current closing price is 0.16% . |
BridgeBio Pharma Fundamentals Correlations and Trends
By evaluating BridgeBio Pharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among BridgeBio Pharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. BridgeBio financial account trend analysis is a perfect complement when working with valuation or volatility modules.About BridgeBio Pharma Stock history
BridgeBio Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for BridgeBio is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in BridgeBio Pharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing BridgeBio Pharma stock prices may prove useful in developing a viable investing in BridgeBio Pharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 162.8 M | 135.5 M | |
| Net Loss | -433.1 M | -454.7 M |
BridgeBio Pharma Quarterly Net Working Capital |
|
BridgeBio Pharma Stock Technical Analysis
BridgeBio Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
BridgeBio Pharma Period Price Range
Low | November 28, 2024
| High |
0.00 | 0.00 |
BridgeBio Pharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
BridgeBio Pharma November 28, 2024 Market Strength
Market strength indicators help investors to evaluate how BridgeBio Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BridgeBio Pharma shares will generate the highest return on investment. By undertsting and applying BridgeBio Pharma stock market strength indicators, traders can identify BridgeBio Pharma entry and exit signals to maximize returns
BridgeBio Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for BridgeBio Pharma's price direction in advance. Along with the technical and fundamental analysis of BridgeBio Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of BridgeBio to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0506 | |||
| Jensen Alpha | 0.0716 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0326 | |||
| Treynor Ratio | 0.1754 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.